US contractor upholds Pacific Edge's Medicare ban

US contractor upholds Pacific Edge's Medicare ban
Pacific Edge has had a fresh blow to its hopes for access to the US Medicare market for Cxbladder diagnostic tests. (Image: Pacific Edge)
Greg Hurrell
Pacific Edge’s flagship Cxbladder cancer testing has been deemed as “not considered medically reasonable and necessary” by the company’s United States Medicare administrator. The statement is in a new proposed Local Coverage Determination (LCD) for Medicare and is a fresh blow for the company’s hopes to quickly regain long-term access to the Medicare system for its bladder cancer tests.Medicare is Pacific Edge’s largest customer.The new LCD was released overnight New Zealand time by Novitas, Pacific Edge...

More Markets

NZX 50 ends the week down 1.5% in flurry of index reweighting
Markets Market close

NZX 50 ends the week down 1.5% in flurry of index reweighting

The S&P/NZX 50 index dropped 89.42 points, or 0.8%, to 11,682.39.

Paul McBeth 21 Jun 2024
KMD Brands guidance undershoots analysts' forecasts
Retail

KMD Brands guidance undershoots analysts' forecasts

Group sales between February and May have fallen 8.4% year-on-year.

Analysts downgrade Channel Infrastructure
Infrastructure

Analysts downgrade Channel Infrastructure

The move follows BP's selling its stake.

Ian Llewellyn 21 Jun 2024
NZ shares rally as economy edges out of recession
Markets Market close

NZ shares rally as economy edges out of recession

The S&P/NZX 50 index rose 100.62 points, or 0.9%, to 11,771.81.

Paul McBeth 20 Jun 2024